Brief: Nanoform: Final Clinical Results

Nanoform Finland Oyj

18/05/2021 06:14

May 18 (Reuters) - Nanoform Finland Plc  NANOFH.HE :
    * NANOFORM'S FINAL CLINICAL RESULTS CONFIRM VALUE
PROPOSITION TO
THE PHARMA INDUSTRY
    * ANNOUNCED COMPLETION AND FINAL RESULTS OF ITS CLINICAL
STUDY
    * PRIMARY, SECONDARY AND OPTIONAL EXPLORATORY OBJECTIVES OF
STUDY
WERE ALL MET
    * NANOFORMED PIROXICAM WAS WELL TOLERATED, WITH NO ADVERSE
EFFECTS
REPORTED
    * SOME ADVERSE EFFECTS WERE SHOWN WITH BOTH OF REFERENCE
PRODUCTS
    * RESULTS SHOW THAT CO'S CESS TECHNOLOGY ENABLED DEVELOPMENT
OF
FAST-ACTING PIROXICAM IMMEDIATE RELEASE (IR) TABLET FORMULATION
WITH MORE RAPID ABSORPTION, IMPROVED DRUG DELIVERY PERFORMANCE

Source text for Eikon:  ID:nWkrsk4n8 
Further company coverage:  NANOFH.HE 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))